ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.

ORR is an index directly measuring the anti-tumor activity of a drug and is the most common endpoint based on tumor measurements, evaluated in single-arm trials.

This article summarized the latest R&D progress of cefroxadine, the Mechanism of Action for cefroxadine, and the drug target R&D trends for cefroxadine.

Overall Survival (OS) is the only endpoint solely based on survival events, fairly objective, and precisely measurable.

Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.

This article summarized the latest R&D progress of diclofenac diethylamine, the Mechanism of Action for diclofenac diethylamine, and the drug target R&D trends for diclofenac diethylamine.

Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.

EMBL-EBI offers a plethora of widely trusted online tools for sequence alignment. Moreover, our emphasis is laid on a profound recommendation: a user-friendly, commercial Patsnap Bio Sequence Database sequence alignment tool, which commendably offers free registration.

The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).

This article summarized the latest R&D progress of cabotegravir/rilpivirine, the Mechanism of Action for cabotegravir/rilpivirine, and the drug target R&D trends for cabotegravir/rilpivirine.

Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.

The role of the MR (Mineralocorticoid Receptor) in the human body is crucial for maintaining electrolyte and fluid balance.